Biotechnology and Genetic Engineering Unit(B G E U)

About Specialized Unit


  • The Biotechnology and Genetic Engineering Unit (BGEU) was established for R&D and process development aimed at lab-scale and limited pilot-scale production of recombinant proteins of commercial importance, especially recombinant biopharmaceutical proteins. Five key recombinant therapeutic proteins—interferon alfa2b, interleukin 12, interferon gamma, growth hormone, and granulocyte colony-stimulating factor—have been successfully produced at the lab scale. R&D efforts have also led to progress in the limited pilot-scale production of some of these proteins. These achievements were made possible through numerous projects funded by the Academy of Science, STDF, and other funding agencies. The BGEU, in collaboration with the Center of Excellence in Recombinant Biopharmaceutical Proteins, aims to serve as an interface between scientific research and the biopharmaceutical and biotechnology industries. One of the unit’s main objectives is the development of molecular diagnostic assays for the detection of infectious and genetic diseases.

    Additionally, the staff's expertise and the facilities at BGEU enable the organization of training programs in cloning, protein expression, molecular diagnostics, and basic molecular techniques.

Mission


To produce high-quality research in the fields of biopharmaceutical production and molecular diagnostics, focusing on their industrial applications and the training of specialized human resources, thereby contributing to the advancement of science and industrial biotechnology in Egypt.

Vision


To be a leading national scientific and technological research center, adhering to international standards and capable of exploiting the vast opportunities offered by advancements in molecular biology and biotechnology.

Structure


Structure

Head of the Unit: Prof. Ehab El-Dabaa Mohamed Sabry
Professor and Head of the Biochemistry and Molecular Biology Department, and Principal Investigator of the Center of Excellence in Recombinant Biopharmaceutical Proteins.

Address: Warak El-Hadar, Kornish El-Nile
P.O. Box: 30 Imbaba, 12411-Giza, Egypt
Cell: +2 01098150568
E-mail: ehabphd@yahoo.com

Founder of the Unit: Prof. Mohamed A. Saber
Emeritus Professor of the Biochemistry and Molecular Biology Department, and Co-Principal Investigator of the Center of Excellence in Recombinant Biopharmaceutical Proteins.

Address: Warak El-Hadar, Kornish El-Nile
P.O. Box: 30 Imbaba, 12411-Giza, Egypt
Cell: +2 0100 147 2845
E-mail: maasaber@yahoo.com


Techniques


Techniques

    A- Recombinant Proteins Production Research

    1. Characterization and cloning of genes using various bioinformatics strategies.
    2. Recombinant protein production in E. coli (lab-scale and limited pilot-scale fermentation up to 5 liters).
    3. Chromatographic purification of recombinant proteins.
    4. Quality assessment of recombinant proteins concerning activity, purity, and biochemical criteria (in collaboration with the Center of Excellence in Recombinant Biopharmaceutical Proteins).

    B- Molecular Diagnosis Research and Services

    1. Customized research for molecular characterization and diagnosis of target genes associated with genetic and infectious diseases.
    2. Development of real-time PCR kits for the quantitative detection of pathogens (viruses, bacteria, and parasites) and genetic diseases.
    3. Routine molecular diagnosis of infectious and genetic diseases using PCR, real-time PCR, reverse hybridization, and other techniques (e.g., HCV, HBV, and others).

Services


  • Routine molecular diagnosis of infectious and genetic diseases using PCR, real-time PCR, reverse hybridization, and other techniques (e.g., HCV, HBV, and others).

  • Training in affiliated fields.

Training


The expertise of the staff and the facilities at GEBU enable the organization of training programs in molecular cloning and gene characterization, molecular diagnosis, bioinformatics, recombinant protein expression and purification, as well as the development of recombinant and DNA vaccines.

Contacts


Name : Prof. Ehab El-Dabaa Mohamed Sabry
  • e.eldabaa@tbri.gov.eg
  • 01098150568